JANESVILLE, Wis.--(BUSINESS WIRE)--SHINE Medical Technologies LLC today announced that it has closed a $150-million Series C-5 financing. Koch Disruptive Technologies (KDT) led the round, which also ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The funds are in support of ...

JANESVILLE, Wis., May 6, 2025 /PRNewswire/ -- SHINE Technologies, a nuclear fusion company with a platform of medical isotope products, announced it has entered into a definitive agreement to acquire ...

Blue Earth Therapeutics will leverage SHINE’s non-carrier added lutetium-177 chloride, Ilumira, in a new treatment for prostate cancer undergoing clinical trials JANESVILLE, Wis., June 6, 2024 ...

SHINE and Zeno enter an MOU to develop radioisotope supply chain for power systems that enable persistent operations from the seabed to the lunar surface JANESVILLE, Wis., June 18, 2024 /PRNewswire/ — ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Shine Technologies has made a ...

Jun. 30—JANESVILLE — SHINE Medical Technologies announced Tuesday it has received a major, $150 million boost as it moves toward completion and commercialization of its Janesville medical nuclear ...

BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver ...

Chrysalis, SHINE’s large-scale irradiation facility, is set to become the largest isotope production facility in the world. Once operational, Chrysalis will complement the existing supply chain ...

BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus” or the "Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians ...